ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
Bmwgsa
|
495 |
112K |
5 |
13:00 |
13:00 |
ASX - By Stock
|
495
|
112K
|
5
|
|
ASX - By Stock
|
HMX |
Re:
Ann: Hammer Executes Earn-in with South32 at Isa Valley Project
|
|
Bmwgsa
|
17 |
6.3K |
2 |
27/05/24 |
27/05/24 |
ASX - By Stock
|
17
|
6.3K
|
2
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
Bmwgsa
|
495 |
112K |
0 |
27/05/24 |
27/05/24 |
ASX - By Stock
|
495
|
112K
|
0
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Investor update
|
|
Bmwgsa
|
86 |
20K |
13 |
17/05/24 |
17/05/24 |
ASX - By Stock
|
86
|
20K
|
13
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust appoints Sergio Duchini as Non-Executive Chairman
|
|
Bmwgsa
|
58 |
15K |
4 |
17/05/24 |
17/05/24 |
ASX - By Stock
|
58
|
15K
|
4
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
Bmwgsa
|
495 |
112K |
3 |
17/05/24 |
17/05/24 |
ASX - By Stock
|
495
|
112K
|
3
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
Bmwgsa
|
495 |
112K |
6 |
17/05/24 |
17/05/24 |
ASX - By Stock
|
495
|
112K
|
6
|
|
ASX - By Stock
|
HMX |
Re:
Copper Price
|
|
Bmwgsa
|
173 |
51K |
2 |
16/05/24 |
16/05/24 |
ASX - By Stock
|
173
|
51K
|
2
|
|
ASX - By Stock
|
HMX |
Re:
Copper Price
|
|
Bmwgsa
|
173 |
51K |
3 |
13/05/24 |
13/05/24 |
ASX - By Stock
|
173
|
51K
|
3
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Board Changes
|
|
Bmwgsa
|
250 |
62K |
9 |
10/05/24 |
10/05/24 |
ASX - By Stock
|
250
|
62K
|
9
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Board Changes
|
|
Bmwgsa
|
250 |
62K |
11 |
09/05/24 |
09/05/24 |
ASX - By Stock
|
250
|
62K
|
11
|
|
ASX - By Stock
|
HMX |
Re:
Copper Price
|
|
Bmwgsa
|
173 |
51K |
7 |
25/04/24 |
25/04/24 |
ASX - By Stock
|
173
|
51K
|
7
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Resignation of Dr Michael Thurn & appointment of John Clark
|
|
Bmwgsa
|
261 |
71K |
16 |
23/04/24 |
23/04/24 |
ASX - By Stock
|
261
|
71K
|
16
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
Bmwgsa
|
1.4K |
358K |
7 |
28/02/24 |
28/02/24 |
ASX - By Stock
|
1.4K
|
358K
|
7
|
|
ASX - By Stock
|
PAA |
Re:
Ann: FDA Provides Clear Feedback for ODD Approval
|
|
Bmwgsa
|
323 |
76K |
8 |
29/01/24 |
29/01/24 |
ASX - By Stock
|
323
|
76K
|
8
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PAA completes Phase 1 and files for Orphan Drug Designation
|
|
Bmwgsa
|
430 |
109K |
21 |
11/01/24 |
11/01/24 |
ASX - By Stock
|
430
|
109K
|
21
|
|
ASX - By Stock
|
PAA |
Re:
Ann: MND Biomarkers and Pharmacodynamics Results
|
|
Bmwgsa
|
396 |
83K |
9 |
04/07/23 |
04/07/23 |
ASX - By Stock
|
396
|
83K
|
9
|
|
ASX - By Stock
|
PAA |
Re:
Ann: MND Biomarkers and Pharmacodynamics Results
|
|
Bmwgsa
|
396 |
83K |
7 |
04/07/23 |
04/07/23 |
ASX - By Stock
|
396
|
83K
|
7
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
Bmwgsa
|
51 |
12K |
16 |
04/07/23 |
04/07/23 |
ASX - By Stock
|
51
|
12K
|
16
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Motor Neurone Disease Clinical Trial Update
|
|
Bmwgsa
|
147 |
34K |
17 |
25/05/23 |
25/05/23 |
ASX - By Stock
|
147
|
34K
|
17
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Motor Neurone Disease Clinical Trial Update
|
|
Bmwgsa
|
147 |
34K |
7 |
23/05/23 |
23/05/23 |
ASX - By Stock
|
147
|
34K
|
7
|
|
ASX - By Stock
|
PAA |
Re:
Ann: MPL has anti-cancer effects across multiple cancer types
|
|
Bmwgsa
|
121 |
26K |
9 |
09/05/23 |
09/05/23 |
ASX - By Stock
|
121
|
26K
|
9
|
|
ASX - By Stock
|
HMX |
Re:
Ann: Trading Halt
|
|
Bmwgsa
|
189 |
63K |
3 |
08/05/23 |
08/05/23 |
ASX - By Stock
|
189
|
63K
|
3
|
|
ASX - By Stock
|
HMX |
Re:
Ann: Kalman Resource Upgrade Lifts CuEq Inventory to over 530KT
|
|
Bmwgsa
|
57 |
23K |
10 |
08/05/23 |
08/05/23 |
ASX - By Stock
|
57
|
23K
|
10
|
|
ASX - By Stock
|
HMX |
Re:
Ann: Response to Price Query
|
|
Bmwgsa
|
128 |
40K |
2 |
03/04/23 |
03/04/23 |
ASX - By Stock
|
128
|
40K
|
2
|
|
ASX - By Stock
|
HMX |
Re:
Ann: Response to Price Query
|
|
Bmwgsa
|
128 |
40K |
1 |
03/04/23 |
03/04/23 |
ASX - By Stock
|
128
|
40K
|
1
|
|
ASX - By Stock
|
HMX |
Re:
Ann: Half Year Financial Report
|
|
Bmwgsa
|
5 |
1.8K |
5 |
13/03/23 |
13/03/23 |
ASX - By Stock
|
5
|
1.8K
|
5
|
|
ASX - By Stock
|
PAA |
Re:
TOP 442 SHAREHOLDERS AS AT 31 AUGUST 2022WITH VARIATIONS
|
|
Bmwgsa
|
30 |
7.5K |
5 |
21/09/22 |
21/09/22 |
ASX - By Stock
|
30
|
7.5K
|
5
|
|
ASX - By Stock
|
PAA |
Re:
TOP 442 SHAREHOLDERS AS AT 31 AUGUST 2022WITH VARIATIONS
|
|
Bmwgsa
|
30 |
7.5K |
10 |
21/09/22 |
21/09/22 |
ASX - By Stock
|
30
|
7.5K
|
10
|
|
ASX - By Stock
|
PAA |
Re:
TOP 442 SHAREHOLDERS AS AT 31 AUGUST 2022WITH VARIATIONS
|
|
Bmwgsa
|
30 |
7.5K |
2 |
06/09/22 |
06/09/22 |
ASX - By Stock
|
30
|
7.5K
|
2
|
|
ASX - By Stock
|
PAA |
Re:
TOP 442 SHAREHOLDERS AS AT 31 AUGUST 2022WITH VARIATIONS
|
|
Bmwgsa
|
30 |
7.5K |
0 |
06/09/22 |
06/09/22 |
ASX - By Stock
|
30
|
7.5K
|
0
|
|